Advanced Medical Isotope Corporation (OTCMKTS:RDGL) Short Interest Up 4,877.8% in July

Key Points

• Advanced Medical Isotope Corporation (OTCMKTS:RDGL) experienced a dramatic increase in short interest of 4,877.8% in July, rising from 900 shares to a total of 44,800 shares by July 15th.
• The stock's trading performance showed 926,879 shares exchanged on Friday, with a current price of $0.13, while its 12-month range is between $0.06 and $0.18.
• Advanced Medical Isotope is associated with Vivos Inc, which develops brachytherapy devices for cancer treatment, focusing on innovative technologies like the RadioGel device.

Advanced Medical Isotope Corporation (OTCMKTS:RDGL - ) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 44,800 shares, agrowthof4,877.8% from the June 30th total of 900 shares. Based on an average daily volume of 2,338,200 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 2,338,200 shares, the short-interest ratio is currently 0.0 days.

Advanced Medical Isotope Price Performance

Shares of RDGL stock traded up $0.01 on Friday, hitting $0.13. 926,879 shares of the company's stock were exchanged, compared to its average volume of 955,491. Advanced Medical Isotope has a 12 month low of $0.06 and a 12 month high of $0.18. The company has a 50 day moving average of $0.13 and a 200 day moving average of $0.12.

About Advanced Medical Isotope

Vivos Inc, a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.